AI Terminal
ABIVAX
Share Issue/Capital Change • Jan 31, 2023
1063_iss_2023-01-31_da7b3e50-09a2-4797-b268-b74790dd60be.pdf
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
NOTICE TO HOLDERS OF BONDS CONVERTIBLE AND/OR EXCHANGEABLE INTO NEW AND/OR EXISTING SHARES (OCEANES) WITH A NOMINAL VALUE OF EUR 24,999,975.99
PARIS, France, January 31, 2023 – 06:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today published the resetting of the Conversion/Exchange Ratio of convertible Bonds and/or exchangeable into new and/or existing shares (OCEANEs) due in 2026, with a nominal value of EUR 24,999,975.99 which were issued by Abivax SA (ISIN FR0014004PT4).
Notice is hereby given to Bondholders of the OCEANEs that, in accordance with Condition 2.6(D) of the terms and conditions of the OCEANEs and in connection with the occurrence of a Reset Date on January 30, 2023, the Conversion/Exchange Ratio will be adjusted from 1 to 1.176, effective as of January 30, 2023, which corresponds to a decrease in the implied conversion/exchange price of the Bonds from EUR 38.19 per share to approximately EUR 32.47 per share. The number of shares underlying the Bonds therefore changed from 654,621 to 769,834.
*****
About Abivax (www.abivax.com)
Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Contacts
Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63
Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24
Investors LifeSci Advisors Ligia Vela-Reid [email protected] +44 7413 825310
Public Relations France Primatice Thomas Roborel de Climens [email protected] +33 6 78 12 97 95
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22
Public Relations USA Rooney Partners LLC Jeanene Timberlake [email protected] +1 646 770 8858